Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Molitor

Showing results (21-30 of 23) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 23 results.
The Biochemical Journal|March 10, 2018
P62/SQSTM1 is a novel leucine-rich repeat kinase 2 (LRRK2) substrate that enhances neuronal toxicityAlexia F Kalogeropulou, Jing Zhao, Marc F Bolliger, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|April 9, 2021
Differential Inhibition of LRRK2 in Parkinson's Disease Patient Blood by a G2019S Selective LRRK2 InhibitorJessica M Bright, Holly J Carlisle, Alyssa M A Toda, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 24, 2025
Central TYK2 inhibition identifies TYK2 as a key neuroimmune modulatorTyler P Molitor, Genki Hayashi, Mei-Yao Lin, et al.
Pageof 3

Showing results (21-30 of 23) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 23 results.
The Biochemical Journal|March 10, 2018
P62/SQSTM1 is a novel leucine-rich repeat kinase 2 (LRRK2) substrate that enhances neuronal toxicityAlexia F Kalogeropulou, Jing Zhao, Marc F Bolliger, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|April 9, 2021
Differential Inhibition of LRRK2 in Parkinson's Disease Patient Blood by a G2019S Selective LRRK2 InhibitorJessica M Bright, Holly J Carlisle, Alyssa M A Toda, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 24, 2025
Central TYK2 inhibition identifies TYK2 as a key neuroimmune modulatorTyler P Molitor, Genki Hayashi, Mei-Yao Lin, et al.
Pageof 3